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Abstract
Background: A method for assessing the model validity of randomised controlled trials of homeopathy is needed.
To date, only conventional standards for assessing intrinsic bias (internal validity) of trials have been invoked, with
little recognition of the special characteristics of homeopathy. We aimed to identify relevant judgmental domains
to use in assessing the model validity of homeopathic treatment (MVHT). We define MVHT as the extent to which
a homeopathic intervention and the main measure of its outcome, as implemented in a randomised controlled
trial (RCT), reflect ‘state-of-the-art’ homeopathic practice.
Methods: Using an iterative process, an international group of experts developed a set of six judgmental domains,
with associated descriptive criteria. The domains address: (I) the rationale for the choice of the particular
homeopathic intervention; (II) the homeopathic principles reflected in the intervention; (III) the extent of
homeopathic practitioner input; (IV) the nature of the main outcome measure; (V) the capability of the main
outcome measure to detect change; (VI) the length of follow-up to the endpoint of the study. Six papers reporting
RCTs of homeopathy of varying design were randomly selected from the literature. A standard form was used to
record each assessor’s independent response per domain, using the optional verdicts ‘Yes’, ‘Unclear’, ‘No’.
Concordance among the eight verdicts per domain, across all six papers, was evaluated using the kappa ()
statistic.
Results: The six judgmental domains enabled MVHT to be assessed with ‘fair’ to ‘almost perfect’ concordance in
each case. For the six RCTs examined, the method allowed MVHT to be classified overall as ‘acceptable’ in three,
‘unclear’ in two, and ‘inadequate’ in one.
Conclusion: Future systematic reviews of RCTs in homeopathy should adopt the MVHT method as part of a
complete appraisal of trial validity.
Background
In systematic reviews, the criteria for defining the quality
of a randomised controlled trial (RCT), as defined by
QUOROM [1] and PRISMA [2] and adopted by the
Cochrane Collaboration [3], are designed to appraise
internal validity (the extent to which the design, conduct
and analysis of a trial has minimised or avoided biases in
its comparison of treatments [4-6]). The external validity
of an RCT (the extent to which the study’s results pro-
vide a correct basis for generalisation to other clinical
circumstances [4-6]) is also important but is less often
addressed by such formal assessment. It is difficult to
optimise both attributes in a single RCT: an explanatory
trial focuses mainly on internal validity, whereas a prag-
matic trial is designed to ensure maximum external valid-
ity. Nevertheless, if the results of an RCT are not
internally valid, the question of external validity may be
regarded as irrelevant; equally, the results of an internally
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valid RCT may be clinically limited if it lacks external
validity [5].
In the field of complementary/alternative medicine
(CAM), it is recognised that a third attribute of an RCT
- its model validity - is also of particular importance
[7,8]. Model validity reflects the concordance between
the trial study design and “state of the art” practice for
the intervention under investigation [4]. In their discus-
sion of RCT methods in CAM, Verhoef and co-authors
go farther, advising that model validity should “encom-
pass ... the unique healing theory and therapeutic con-
text of the intervention” [7].
In reviewing RCTs in homeopathy, internal validity
has been appraised using either Jadad scores [9] or
Cochrane-based criteria [10]. The external validity of
this body of literature has also been addressed [11].
However, the ‘homeopathicity’ [12] of the therapeutic
modality and of the clinical outcome measure/s used
(i.e. the key characteristics of model validity) have never
been formally accounted for in the assessment of trial
quality. Some homeopathy trials have been broadly criti-
cised for their lack of acceptable model validity, e.g.:
homeopathic complex medication in female infertility
[13,14]; individualised homeopathic treatment of child-
hood asthma [15,16]; isopathic treatment of hay fever
[17,18]. Recognising that the characteristics of the
homeopathic intervention and outcome measures are
important seems a prerequisite for developing the most
refined and relevant approaches to systematic review in
this field of clinical research.
A set of guidelines (RedHot) [19] has established cri-
teria for reporting data on homeopathic treatments; a
similar set of reporting criteria is available for clinical
trials of acupuncture (STRICTA) [20]. Recommendations
of this nature are important since they require reporting
of methodological details not addressed by generic stan-
dards such as CONSORT [21]. Nevertheless, the RedHot
guidelines for homeopathy do not provide the means to
define or assess model validity.
The work of Verhoef and colleagues highlights the
importance of model validity, and they offer four broad
headings under which assessment of homeopathy RCTs
might take place: “representativeness"; “equipoise and
credibility"; “model congruity"; “context” [7]. These attri-
butes are a suitable reflection of the key characteristics
of homeopathy that must be assessed for model validity,
but they do not provide a direct means to undertake a
practical formal assessment. The importance of such
undertaking has been emphasised in two papers by
Bornhöft and colleagues [4,22], who expressed concern
that the current research literature - and thus the sys-
tematic review of it - may contain high risk of false
negative results.
We addressed this issue by creating and testing a
practical set of judgmental domains and accompanying
criteria that may be used, within systematic review, to
appraise RCTs for model validity of homeopathic treat-
ment (MVHT). For the purpose of this work, we define
MVHT as the extent to which a homeopathic interven-
tion and the main measure of its outcome, as imple-
mented in an RCT, reflect ‘state-of-the-art’ clinical
practice in homeopathy [4].
Methods and results
Preliminary set of domains
A set of six domains for assessing MVHT was drafted,
based on the checklist proposed by Bornhöft et al. [4].
This draft was considered, round a conference table, by
the full membership of the International Scientific Com-
mittee for Homeopathic Investigations (ISCHI) during its
meeting in October 2010, Paris, France. Each member of
the committee is an experienced homeopathic practi-
tioner and/or researcher. Following detailed discussion
amongst the group, a set of draft assessment domains
was proposed as follows:
Domain I: Is the condition amenable to homeo-
pathic intervention?
Domain II: Is the specific intervention used consis-
tent with homeopathic principles?
Domain III: Would the rationale for the interven-
tion used be supported by a significant body of
homeopathic practitioners?
Domain IV: Does the main outcome measure reflect
the key effects expected of the intervention used?
Domain V: Is the main outcome measure capable of
detecting change?
Domain VI: Is the length of follow-up for the main
outcome appropriate to detect the intended effect of
the intervention used?
Based on these six draft domains, the 10 group mem-
bers who are homeopathic practitioners/researchers
(representing Europe [n = 5], USA, [n = 3], Brazil [n = 1]
and India [n = 1]) then participated in appraising relevant
methodological facts about three placebo-controlled
RCTs of homeopathic treatment published in the peer-
reviewed literature [23-25]. The following summary facts
were provided per trial: nature of the homeopathic inter-
vention (treatment modality; potency of medicine); main
outcome measure and its timing. Full texts of the papers
were not supplied. The trials were selected to represent
at least one example of individualised (classical) homeop-
athy and at least one example of non-individualised
homeopathy (the same single/complex homeopathic
medicine for every trial participant).
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Each ISCHI member independently assessed each trial,
recording their verdicts on each of the above six
domains with the answers ‘Yes’, ‘No’, or ‘Unclear’. Those
judgments were then shared with the entire group and
the information (anonymised) noted on a flip-chart.
Members did not vote on any RCT in which he/she is a
co-author.
The majority views were:
Ferley [23]. RCT of Oscillococcinum in influenza was
clearly acceptable in five of the six domains, but was
unclear as regards the homeopathic nature of the
intervention (domain II).
Jacobs [24]. RCT of individualised homeopathy for
childhood diarrhoea was acceptable in all domains of
MVHT.
Schmidt [25]. RCT of Thyroidinum for body weight
reduction was inadequate in domain I and domain
VI and was unclear in domains II-V.
Refined set of domains and judgmental criteria
Some important discrepancies of interpretation between
assessors were acknowledged at the above meeting and
so the domains and their associated judgmental criteria
were refined subsequently. The aim was to determine a
set of domains and criteria whose style mirrors that
used by the Cochrane Collaboration for assessing risk-
of-bias (internal validity) [3].
From further discussion within the ISCHI membership
and with other colleagues (see Acknowledgements), six
revised domains were agreed upon. These comprised
the following wording (with associated judgmental cri-
teria provided per domain - details in Table 1):
Domain I (Rationale): Would a significant body of
accredited homeopaths support the rationale for the
intervention used in the study?
Domain II (Principles): Is the specific intervention
used consistent with homeopathic principles?
Domain III (Practitioner): Does the study have sui-
tably qualified and experienced homeopathic practi-
tioner input?
Domain IV (Outcome measure): Does the main
outcome measure reflect the main effect expected of
the intervention used?
Domain V (Sensitivity): Is the main outcome mea-
sure capable of detecting change?
Domain VI (Follow-up): Is the length of follow-up
for the main outcome measure appropriate to detect
the intended effect of the intervention?
To characterise and test this refined method in prac-
tice, another six RCTs of homeopathic treatment were
selected randomly from the peer-reviewed journal litera-
ture, ensuring that individualised homeopathy was the
subject of investigation in at least two: five were pla-
cebo-controlled [26-30], and one used active control
[31]. Eight members of our group then appraised these
RCTs, based on full texts of the six papers; summary
information about each trial was also provided to them
(Table 2) by the study coordinator (RTM). The results
reported in each paper were not taken into account in
the assessment process, though the assessors were not
formally blinded to the Results or Discussion sections in
each case. In papers where a single primary outcome
had not been pre-defined by a trial’s authors, a ‘main’
outcome measure was identified for that trial using the
hierarchical structure given in the WHO International
Classification of Functioning, Disability and Health [32]:
for the six papers examined, a single primary outcome
had not been pre-defined in three cases [26-28].
The eight assessors submitted their independent ver-
dicts, via e-mail on a standard form, to the study coordi-
nator. The total numbers of verdicts (‘Yes’, ‘Unclear’,
‘No’) recorded per domain are listed in Table 3. The
table also shows the concordance among the eight asses-
sors in their verdict per domain. This is presented using
Fleiss’s normalised measure of overall multi-rater agree-
ment, corrected for the amount expected by chance: the
kappa () statistic [33], calculated using Microsoft Excel.
The value of  (whose arithmetic range is 0 [no agree-
ment] to 1 [perfect agreement]) varied from 0.42
(domain III) to 0.94 (domain V): see Table 3.
Table 4 presents the same verdicts as Table 3, but
focused per paper to highlight the majority verdict per
domain. The most common majority verdict was ‘Yes’,
which occurred in a total of 30 out of 36 instances. One
trial (Lewith [26]) attained a majority of ‘No’ in one
domain; two trials (Kainz [27], McCutcheon [28]) each
contained one or more ‘Unclear’ in the majority verdicts;
the remaining three trials (Adler [31], Bell [29], Robert-
son [30]) each comprised a full complement of six ‘Yes’
majority verdicts. Table 4 also itemises the overall
majority verdict per paper (reflecting number of
domains with majority responses ‘Yes’, ‘Unclear’, ‘No’).
Discussion
Our international group of homeopathic practitioners/
researchers has successfully identified a set of six key
domains of RCTs that enables the appraisal of MVHT.
Domains I-III address the ‘homeopathicity’ [12] of an
RCT, while domains IV-VI address aspects of validity
that are also germane to an RCT of any medical ther-
apy. Even from the sample of just six homeopathy RCTs
evaluated here by eight homeopathy specialists, it is evi-
dent that appraisal of key aspects of MVHT can be
achieved using our proposed method.
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Table 1 Refined domains and criteria used to assess RCTs for model validity of homeopathic treatment (MVHT)a
Domain I (Rationale). Would a significant body of accredited homeopaths support the rationale for the intervention used in the study? b,
c
Criteria for a judgment of ‘Yes’ (i.e. acceptable
MVHT for this domain)
Both of the following:
• Clinical knowledge and practice inform that, for the condition under investigation, the health
of patients may be benefited by homeopathic intervention.
• A substantial number of experienced homeopaths would support the choice of this
intervention for this type of patient.
Criteria for a judgment of ‘No’ (i.e. inadequate
MVHT for this domain)
One or both of the following:
• Clinical knowledge and practice do not inform that, for the condition under investigation, the
health of patients may be benefited by homeopathic intervention.
• A substantial number of experienced homeopaths would not support the choice of this
intervention for this type of patient.
Criteria for a judgment of ‘Unclear’ (i.e.
uncertain MVHT for this domain)
One of the following:
• There are likely to be important differences amongst experienced homeopathic opinion on
the rationale for the intervention used.
• Insufficient information to permit judgment of ‘Yes’ or ‘No’.
Domain II (Principles). Is the specific intervention used consistent with homeopathic principles?
Criteria for a judgment of ‘Yes’ (i.e. acceptable
MVHT for this domain)
One or both of the following:
• The intervention used is based on the principle of ‘like treats like’ or it is based on the
principle of isopathy (i.e. use of homeopathic biotherapy, endogenous molecule or aetiological
substance).
• Literature sources (materia medica, repertory, etc.) are available that convincingly justify the
specific intervention.
Criteria for a judgment of ‘No’ (i.e. inadequate
MVHT for this domain)
One or both of the following:
• The intervention used is not based on the principle of ‘like treats like’ or it is not based on
the principle of isopathy (i.e. use of homeopathic biotherapy, endogenous molecule or
aetiological substance).
• Literature sources do not convincingly justify the specific intervention.
Criterion for a judgment of ‘Unclear’ (i.e.
uncertain MVHT for this domain)
• Insufficient information to permit judgment of ‘Yes’ or ‘No’.
Domain III (Practitioner). Does the study have suitably qualified and experienced homeopathic practitioner input?
Criteria for a judgment of ‘Yes’ (i.e. acceptable
MVHT for this domain)
Either of the following, as appropriate: d
• Individualised homeopathy: Those who have prescribed the homeopathic medicine(s) in this
case are suitably trainede and experienced in homeopathy to manage the condition under
investigation.
• Non-individualised homeopathy: There is evidence that experienced homeopathic input (and/
or a suitable literature source - e.g. materia medica, repertory) has been involved in informing
the choice of the medicine(s) used commonly for all patients in the study.
Criteria for a judgment of ‘No’ (i.e. inadequate
MVHT for this domain)
Either of the following, as appropriate:
• Individualised homeopathy: Those who have prescribed the homeopathic medicine(s) in this
case are not suitably trained and experienced in homeopathy to manage the condition under
investigation.
• Non-individualised homeopathy: There is evidence that experienced homeopathic input (or a
suitable literature source - e.g. materia medica, repertory) has not been involved in informing
the choice of the medicine(s) used commonly for all patients in the study.
Criterion for a judgment of ‘Unclear’ (i.e.
uncertain MVHT for this domain)
• Insufficient information to permit judgment of ‘Yes’ or ‘No’.
Domain IV (Outcome measure). Does the main outcome measure reflect the main effect expected of the intervention used?
Criterion for a judgment of ‘Yes’ (i.e.
acceptable MVHT for this domain)
• The main clinical effect expected of the intervention is adequately measured by the main
outcome used.
Criterion for a judgment of ‘No’ (i.e.
inadequate MVHT for this domain)
• The main clinical effect expected of the intervention is not adequately measured by the main
outcome used.
Criterion for a judgment of ‘Unclear’ (i.e.
uncertain MVHT for this domain)
• Insufficient information to permit judgment of ‘Yes’ or ‘No’.
Domain V (Sensitivity). Is the main outcome measure capable of detecting change?
Criteria for a judgment of ‘Yes’ (i.e. acceptable
MVHT for this domain)
All of the following:
• The main outcome measure is sensitive to changes of the magnitude expected in the
patients under investigation.
• The main outcome measure is capable of determining both improvement and deterioration.
• The main outcome measure shows no evidence of a ‘floor effect’ and/or ‘ceiling effect’.f
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According to accepted guidelines [34,35], the magni-
tude of the kappa statistic reflects inter-rater agreement
as follows:  = 0.01-0.20, slight,  = 0.21-0.40, fair;  =
0.41-0.60, moderate;  = 0.61-0.80, substantial;  = 0.81-
0.99, almost perfect. Thus, concordance among assessors
was ‘fair’ for domains I, III and VI ( = 0.42-0.50), ‘mod-
erate’ for domain II ( = 0.68), and ‘almost perfect’ for
domains IV and V ( = 0.92-0.94). It remains to be seen
whether disparity of opinion is intrinsic to the complexity
of the underlying concepts and/or to any lack of clarity in
the particular wording of the domain and criteria
descriptions. It is usual, however, to find only limited
concordance amongst independent assessors in the judg-
ment of subjectively-based domains [35]. Nevertheless, if
ambiguity of wording does become evident, a set of
revised descriptions would be drafted and published.
In our use of the method, one trial (Lewith [26])
attained a majority of ‘No’, in domain I (rationale), which
indicates that assessors regarded it unlikely that allergic
asthma patients can be benefited by homeopathy per se
Table 1 Refined domains and criteria used to assess RCTs for model validity of homeopathic treatment (MVHT)a
(Continued)
Criteria for a judgment of ‘No’ (i.e. inadequate
MVHT for this domain)
Any one or more of the following:
• The main outcome measure is not sensitive to changes of the magnitude expected in the
patients under investigation.
• The main outcome measure is not capable of determining both improvement and
deterioration.
• The main outcome measure shows evidence of a ‘floor effect’ and/or ‘ceiling effect’.
Criterion for a judgment of ‘Unclear’ (i.e.
uncertain MVHT for this domain)
• Insufficient information to permit judgment of ‘Yes’ or ‘No’.
Domain VI (Follow-up). Is the length of follow-up for the main outcome measure appropriate to detect the intended effect of the
intervention?
Criterion for a judgment of ‘Yes’ (i.e.
acceptable MVHT for this domain)
• The time-point selected for main follow-up measurement provides sufficient opportunity for a
clinical change to be observed.
Criterion for a judgment of ‘No’ (i.e.
inadequate MVHT for this domain)
• The time-point selected for main follow-up measurement does not provide sufficient
opportunity for a clinical change to be observed.
Criterion for a judgment of ‘Unclear’ (i.e.
uncertain MVHT for this domain)
• Insufficient information to permit judgment of ‘Yes’ or ‘No’.
aGiven the prior assessment that medicines used were prepared according to homeopathic pharmaceutical practice
bThe assessment should reflect whether the rationale for the intervention could feasibly apply to each and every patient studied
cA novel homeopathic medicine might be eligible to fulfil the criteria for ‘Yes’ in circumstances where the toxicology or proving symptoms support its use,
according to the Principle of Similars, in the study sample
dThe initially refined Domain III did not include the criteria sub-divisions ‘Individualised homeopathy’ and ‘Non-individualised homeopathy’. Some difficulty
resulted initially in the ensuing assessments, and so the papers were reappraised, for Domain III only, with the subdivisions added (with the consequent findings
as reported in Table 3 and Table 4)
e’Suitably trained’: To enable this assessment, the experience, accreditation and qualifications of the practitioners must be stated in the original paper (as per the
RedHot guidelines - Homeopathy 2007; 96:42-45)
fThe outcome measure does not reach a minimum (i.e. ‘floor effect’) and/or a maximum (i.e. ‘ceiling effect’) value, making it incapable of detecting change across
the entire clinically meaningful range of the study sample
Table 2 Summary information per RCT assessed for MVHT using refined set of domains and judgmental criteria













Allergic asthma House dust mite Placebo Asthma VAS 16 wk
Kainz, 1996 [27] Warts Individualised
(from 10 options)
Placebo Responders: patients with at least 50% reduction in area






Placebo State Anxiety score 15 d
Bell, 2004 [29] Fibromyalgia Individualised Placebo Tender point pain on palpation 3 mo
Robertson, 2007
[30]
Post-operative pain Arnica montana Placebo Change in tonsillectomy pain score (VAS) 14 d
Adler, 2009 [31] Depression Individualised Fluoxetine Change in MADRS score from baseline 8 wk
’Main’ outcome measure was identified per RCT using the WHO International Classification of Functioning, Disability and Health, 2002 [32]
MADRS Montgomery & Åsberg Depression Rating Scale
VAS Visual Analogue Scale
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Table 3 Verdicts for domains I-VI, indicating number of
assessors rating ‘Yes’, ‘Unclear’, or ‘No’ per paper, and
the kappa statistic (κ) per domain
Domain I (Rationale)
 = 0.50
Paper Yes Unclear No
Lewith 3 1 4
Kainz 6 2 0
McCutcheon 2 4 2
Bell 8 0 0
Robertson 6 1 1
Adler 8 0 0
Domain II (Principles)
 = 0.68
Paper Yes Unclear No
Lewith 7 1 0
Kainz 7 1 0
McCutcheon 2 5 1
Bell 8 0 0
Robertson 6 0 2
Adler 8 0 0
Domain III (Practitioner)
 = 0.42
Paper Yes Unclear No
Lewith 6 1 1
Kainz 5 3 0
McCutcheon 1 4 3
Bell 8 0 0
Robertson 4 2 2
Adler 7 1 0
Domain IV (Outcome measure)
 = 0.92
Paper Yes Unclear No
Lewith 6 2 0
Kainz 8 0 0
McCutcheon 7 1 0
Bell 8 0 0
Robertson 7 0 1
Adler 8 0 0
Domain V (Sensitivity)
 = 0.94
Paper Yes Unclear No
Lewith 8 0 0
Kainz 8 0 0
McCutcheon 4 3 1
Bell 8 0 0
Robertson 7 1 0
Adler 8 0 0
Table 3 Verdicts for domains I-VI, indicating number of
assessors rating ‘Yes’, ‘Unclear’, or ‘No’ per paper, and
the kappa statistic (κ) per domain (Continued)
Domain VI (Follow-up)
 = 0.43
Paper Yes Unclear No
Lewith 5 1 2
Kainz 4 4 0
McCutcheon 3 3 2
Bell 8 0 0
Robertson 8 0 0
Adler 6 1 1
Table 4 Verdicts for each of six RCTs, indicating number
of assessors rating ‘Yes’ (Y), ‘Unclear’ (U), or ‘No’ (N) per
domain
Lewith, 2002 [26]
Domain Yes Uncertain No Majority
I (Rationale) 3 1 4 N
II (Principles) 7 1 0 Y
III (Practitioner) 6 1 1 Y
IV (Outcome measure) 6 2 0 Y
V (Sensitivity) 8 0 0 Y
VI (Follow-up) 5 1 2 Y
Overall majority verdict 5Y+1N
Kainz, 1996 [27]
Domain Yes Uncertain No Majority
I (Rationale) 6 2 0 Y
II (Principles) 7 1 0 Y
III (Practitioner) 5 3 0 Y
IV (Outcome measure) 8 0 0 Y
V (Sensitivity) 8 0 0 Y
VI (Follow-up) 4 4 0 U*
Overall majority verdict 5Y+1U
McCutcheon, 1996 [28]
Domain Yes Uncertain No Majority
I (Rationale) 2 4 2 U
II (Principles) 2 5 1 U
III (Practitioner) 1 4 3 U
IV (Outcome measure) 7 1 0 Y
V (Sensitivity) 4 3 1 Y
VI (Follow-up) 3 3 2 U*
Overall majority verdict 2Y+4U
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and/or by the particular homeopathic regimen used in
this trial; we would therefore class this trial overall as
‘inadequate MVHT’. It is noteworthy that this trial did
not fail our MVHT assessment on the basis of domain II
and/or domain III (i.e. isopathy using house dust mite is
consistent with homeopathic principles, and the study
had suitably qualified and experienced homeopathic
practitioner input). It was on the basis of perceived defi-
ciencies in all three of the above attributes that led to
previous adverse conclusions on this trial using non-for-
malised criteria for model validity [36]. Two trials (Kainz
[27], McCutcheon [28]) were rated as ‘unclear’ in one or
more domains and so may be classed overall as ‘unclear
MVHT’. The remaining three trials (Bell [29], Robertson
[30], Adler [31]) each received a full complement of six
‘Yes’ majority verdicts and so may be classed overall as
‘acceptable MVHT’.
This proposed method for appraising and summarising
MVHT harmonises with the Cochrane Collaboration’s
technique for assessing risk-of-bias for internal validity.
In the Cochrane approach, a trial is assessed against
seven domains: sequence generation; allocation conceal-
ment; blinding of participants and personnel; blinding of
outcome assessors; incomplete outcome data; freedom
from selective reporting; freedom from other bias. For
each domain, risk-of-bias is indicated by the response
‘low risk’, ‘unclear risk’ or ‘high risk’; an overall classifica-
tion of risk-of-bias per trial is then identified using the
same terminology [3].
The formal appraisal of RCTs, as adopted by the
Cochrane Collaboration for risk-of-bias (internal valid-
ity), is typically by consensus between or among assessors,
not by majority. In our test of the new method, it was not
our purpose to seek consensus but to identify a summary
verdict per domain and thus to classify MVHT overall
for each of six RCTs. In systematic review it is not
assumed that each independent assessor will arrive initi-
ally at the same judgment per domain; the method for
assessing MVHT would operate in the same manner, and
we recommend using three assessors to account for
diversity of homeopathic opinion. Despite the diverse
nature of homeopathic practice, there is little reason to
anticipate undue difficulty in the ability of three specia-
lists - even those from differing ‘schools’ of homeopathic
theory and practice - to achieve a reasonable consensus
agreement in judging the relevant issues. As was intended
in our approach here, the formal appraisal of MVHT
would necessarily exclude the consideration of the trial
results themselves, and it might be appropriate to conceal
the Results and Discussion sections, as well as the
authors’ names, in the papers that are provided to
assessors.
In initial consideration of our criteria for domain III
(practitioner), some of our group expressed concern
that published RCTs seldom include any account of the
homeopathic prescribing rationale or approach to indivi-
dualisation. After discussion, it was agreed that to insist
on full information, such as repertorisation details,
exceeds expectation of the current research literature in
homeopathy as well as the typical word limits of journal
papers. Moreover, we note that the RedHot guidelines
include clear recommendations with respect to indivi-
dualised homeopathic prescribing [19], and we encou-
rage authors of RCTs to implement these high reporting
standards. We adopted the more generic domain III
judgmental criteria, as given in Table 1.
Additional discussion emerged about whether RCTs of
homeopathy adequately take into account the complexity
of individuals whose totality of signs and symptoms,
rather than a named medical condition per se, is the basis
of a homeopathic prescription. While we agreed this is
Table 4 Verdicts for each of six RCTs, indicating number
of assessors rating ‘Yes’ (Y), ‘Unclear’ (U), or ‘No’ (N) per
domain (Continued)
Bell, 2004 [29]
Domain Yes Uncertain No Majority
I (Rationale) 8 0 0 Y
II (Principles) 8 0 0 Y
III (Practitioner) 8 0 0 Y
IV (Outcome measure) 8 0 0 Y
V (Sensitivity) 8 0 0 Y
VI (Follow-up) 8 0 0 Y
Overall majority verdict 6Y
Robertson, 2007 [30]
Domain Yes Uncertain No Majority
I (Rationale) 6 1 1 Y
II (Principles) 6 0 2 Y
III (Practitioner) 4 2 2 Y
IV (Outcome measure) 7 0 1 Y
V (Sensitivity) 7 1 0 Y
VI (Follow-up) 8 0 0 Y
Overall majority verdict 6Y
Adler, 2009 [31]
Domain Yes Uncertain No Majority
I (Rationale) 8 0 0 Y
II (Principles) 8 0 0 Y
III (Practitioner) 7 1 0 Y
IV (Outcome measure) 8 0 0 Y
V (Sensitivity) 8 0 0 Y
VI (Follow-up) 6 1 1 Y
Overall majority verdict 6Y
*: In the case of tied majority between the two verdicts Y and U, the lower-
ranked of the two (U) was used to reflect the rating of that domain: see
domain VI (Kainz, McCutcheon)
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an important facet of future research development, we
accepted that the question whether clinical trials of
homeopathy should place more emphasis on grouping
together individuals with given characteristic signs and/
or symptoms, rather than subjects with a specified medi-
cal condition, lies outside the terms of reference of the
current project.
In judging domains IV-VI (outcome measure, sensi-
tivity, follow-up) solely on a single ‘main’ outcome, we
recognise that alternative outcome measures in the stu-
dies might have been selected and might have received
different verdicts in our assessment of MVHT. Our
approach here is consistent with the fact that a single,
pre-determined, primary outcome is an important ele-
ment in judging the validity of a trial. Our use of the
WHO’s International Classification of Functioning,
Disability and Health, as became necessary for three of
the six papers, has at least enabled us to make objec-
tive decisions on relative importance of health attri-
butes within a clear hierarchical structure. For domain
IV (whether the main outcome measure reflects the
main effect expected of the intervention used), it is
important that the consideration of ‘expected main
effect’ also embraces the whole-person nature of the
intervention and its associated outcome [37] - espe-
cially for homeopathy trials that involve individualised
patient prescribing. Future assessments of MVHT of
published trials should, where appropriate, include
such ‘whole-person’ consideration, which might be
achieved by extending the criteria by which ‘main out-
come measure’ is selected [38]. This initiative might, in
turn, assist the planning of future homeopathy trials by
sharpening researchers’ focus on the relevance of the
outcome measures used.
Together with Cochrane-style assessment of risk-of-
bias regarding internal validity, the assessment of external
validity using the methods of either Bornhöft [4] or Jonas
[11], and the RedHot guidelines for reporting [19], the
domains and criteria we propose for appraising MVHT
can enable a complete critical appraisal of appropriate
RCTs in homeopathy. For reviews aiming to assess
model validity in other types of RCT (e.g. prophylaxis
rather than treatment) or in addressing a different
research question (e.g. “Do molecular and ultra-molecu-
lar homeopathic potencies differ in their clinical
effects?”), the domains/criteria we propose here are likely
to require suitable adaptation. In any event, as suggested
above, some modification of the currently proposed
descriptions may be necessary in the light of experience
in applying them in systematic reviews. With further sui-
table amendment, the approach we propose would also
be relevant for assessing model validity in RCTs of com-
plex interventions more generally, including other CAM
disciplines.
Conclusion
Six novel judgmental domains enabled MVHT to be
assessed with ‘fair’ to ‘almost perfect’ concordance in
each case. For the six RCTs examined, the method
allowed MVHT to be classified overall as ‘acceptable’ in
three, ‘unclear’ in two, and ‘inadequate’ in one. The
MVHT assessment method should be applied in future
systematic reviews of RCTs in homeopathy.
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